Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA Grants Breakthrough Therapy Designation to Exelixis’ Cabozantinib for the Treatment of Renal Cell Carcinoma in Patients Who Received One Prior Therapy
FDA Grants Breakthrough Therapy Designation to Exelixis’ Cabozantinib for the Treatment of Renal Cell Carcinoma in Patients Who Received One Prior Therapy
FDA Grants Breakthrough Therapy Designation to Exelixis’ Cabozantinib for the Treatment of Renal Cell Carcinoma in Patients Who Received One Prior Therapy
Submitted by
admin
on August 24, 2015 - 11:26am
Source:
Yahoo
News Tags:
FDA
Exelixis
breakthrough therapies
renal cell carcinoma
cabozantinib
Headline:
FDA Grants Breakthrough Therapy Designation to Exelixis’ Cabozantinib for the Treatment of Renal Cell Carcinoma in Patients Who Received One Prior Therapy
Do Not Allow Advertisers to Use My Personal information
